Trial
NCT00865566
Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators
HIV Vaccine Trials Network
Condition
HIV Infections
Intervention
DNA plasmid vaccine
Why stopped
The trial was stopped for efficacy futility
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-10-15